Coagulation in Brain Tumors

Biological Basis and Clinical Implications

Chiara Mandoj, Luigi Tomao, Laura Conti

Research output: Contribution to journalReview article

Abstract

Cancer patients commonly show abnormal laboratory coagulation tests, indicating a subclinical hypercoagulable condition that contribute to morbidity and mortality. The hypercoagulation status not only increases the risk of thromboembolic events but also influences the tumor biology promoting its growth and progression by stimulating intracellular signaling pathways. Recent molecular studies characterized the role of oncogene and suppressor gene in activating clotting pathways, as an integral feature of the neoplastic transformation. It is now clear how haemostatic processes, activated by cancer cells harboring oncogenic mutations, rely on the molecular profile of a particular malignancy, an aspect particularly evident in the differential coagulome profiles showed by different molecular subtypes of brain tumors, such as glioblastoma and medulloblastoma. This review focuses on the biological and clinical aspects of haemostasis in cancer with particular regard on brain tumors.

Original languageEnglish
Pages (from-to)181
JournalFrontiers in Neurology
Volume10
DOIs
Publication statusPublished - Mar 18 2019

Fingerprint

Brain Neoplasms
Neoplasms
Suppressor Genes
Medulloblastoma
Hemostatics
Glioblastoma
Hemostasis
Oncogenes
Morbidity
Mutation
Mortality
Growth

Cite this

Coagulation in Brain Tumors : Biological Basis and Clinical Implications. / Mandoj, Chiara; Tomao, Luigi; Conti, Laura.

In: Frontiers in Neurology, Vol. 10, 18.03.2019, p. 181.

Research output: Contribution to journalReview article

@article{8438720496624fadba478b49b2218b69,
title = "Coagulation in Brain Tumors: Biological Basis and Clinical Implications",
abstract = "Cancer patients commonly show abnormal laboratory coagulation tests, indicating a subclinical hypercoagulable condition that contribute to morbidity and mortality. The hypercoagulation status not only increases the risk of thromboembolic events but also influences the tumor biology promoting its growth and progression by stimulating intracellular signaling pathways. Recent molecular studies characterized the role of oncogene and suppressor gene in activating clotting pathways, as an integral feature of the neoplastic transformation. It is now clear how haemostatic processes, activated by cancer cells harboring oncogenic mutations, rely on the molecular profile of a particular malignancy, an aspect particularly evident in the differential coagulome profiles showed by different molecular subtypes of brain tumors, such as glioblastoma and medulloblastoma. This review focuses on the biological and clinical aspects of haemostasis in cancer with particular regard on brain tumors.",
author = "Chiara Mandoj and Luigi Tomao and Laura Conti",
year = "2019",
month = "3",
day = "18",
doi = "10.3389/fneur.2019.00181",
language = "English",
volume = "10",
pages = "181",
journal = "Frontiers in Neurology",
issn = "1664-2295",
publisher = "Frontiers Research Foundation",

}

TY - JOUR

T1 - Coagulation in Brain Tumors

T2 - Biological Basis and Clinical Implications

AU - Mandoj, Chiara

AU - Tomao, Luigi

AU - Conti, Laura

PY - 2019/3/18

Y1 - 2019/3/18

N2 - Cancer patients commonly show abnormal laboratory coagulation tests, indicating a subclinical hypercoagulable condition that contribute to morbidity and mortality. The hypercoagulation status not only increases the risk of thromboembolic events but also influences the tumor biology promoting its growth and progression by stimulating intracellular signaling pathways. Recent molecular studies characterized the role of oncogene and suppressor gene in activating clotting pathways, as an integral feature of the neoplastic transformation. It is now clear how haemostatic processes, activated by cancer cells harboring oncogenic mutations, rely on the molecular profile of a particular malignancy, an aspect particularly evident in the differential coagulome profiles showed by different molecular subtypes of brain tumors, such as glioblastoma and medulloblastoma. This review focuses on the biological and clinical aspects of haemostasis in cancer with particular regard on brain tumors.

AB - Cancer patients commonly show abnormal laboratory coagulation tests, indicating a subclinical hypercoagulable condition that contribute to morbidity and mortality. The hypercoagulation status not only increases the risk of thromboembolic events but also influences the tumor biology promoting its growth and progression by stimulating intracellular signaling pathways. Recent molecular studies characterized the role of oncogene and suppressor gene in activating clotting pathways, as an integral feature of the neoplastic transformation. It is now clear how haemostatic processes, activated by cancer cells harboring oncogenic mutations, rely on the molecular profile of a particular malignancy, an aspect particularly evident in the differential coagulome profiles showed by different molecular subtypes of brain tumors, such as glioblastoma and medulloblastoma. This review focuses on the biological and clinical aspects of haemostasis in cancer with particular regard on brain tumors.

U2 - 10.3389/fneur.2019.00181

DO - 10.3389/fneur.2019.00181

M3 - Review article

VL - 10

SP - 181

JO - Frontiers in Neurology

JF - Frontiers in Neurology

SN - 1664-2295

ER -